Long term impact of vonoprazan‐based Helicobacter pylori treatment on gut microbiota and its relation to post‐treatment body weight changes
- 6 September 2021
- journal article
- research article
- Published by Wiley in Helicobacter
- Vol. 26 (6) , e12851
Abstract
Background: Vonoprazan‐based Helicobacter pylori (H. pylori) treatment is highly effective in eradicating the target bacteria; however, its post‐1‐year impact on gut microbiota is unknown. This study evaluated the impact of vonoprazan‐based H. pylori therapy on gut microbiota 1‐year post‐therapy and investigated the relationship between body weight changes and post‐therapy gut microbiota perturbations.Materials and Methods: Between March and May 2019, 43 patients with H. pylori infections received either vonoprazan/amoxicillin (VA) or vonoprazan/amoxicillin/clarithromycin (VAC) therapy. Fecal samples were collected prior to treatment and 1 year after treatment. The alpha and beta diversities and the bacterial taxa composition ratios were determined using polymerase chain reaction amplification of the V3–V4 region of the 16S ribosomal RNA gene. The correlation between body weight changes and relative abundances of genera post‐therapy was also analyzed.Results: Among the 43 patients, 18 received VA therapy and 21 received VAC therapy. One year after treatment, the alpha diversity was significantly higher in both the treatment groups (p < .001, using observed operational taxonomic units and Chao1 index), and beta diversity was significantly different in both the groups (p = .001, using unweighted UniFrac distance) compared with baseline findings. Significant positive correlations were found between body weight changes and the relative abundances of Coprococcus spp. (p = .037) and Odoribacter spp. (p = .022) post‐therapy.Conclusion: Vonoprazan‐based H. pylori therapies are associated with long‐term impacts on gut microbiota, including effects on bacterial species richness, and potentially affect metabolism by altering the microbiota. Trial registration number: UMIN000040025.Keywords
This publication has 42 references indexed in Scilit:
- Impact of the gut microbiota on the development of obesity and type 2 diabetes mellitusFrontiers in Microbiology, 2014
- Adjunct antibiotic combination therapy for steroid‐refractory or ‐dependent ulcerative colitis: an open‐label multicentre studyAlimentary Pharmacology & Therapeutics, 2014
- Long-Term Alteration of Intestinal Microbiota in Patients with Ulcerative Colitis by Antibiotic Combination TherapyPLOS ONE, 2014
- Metabolic consequences ofHelicobacter pyloriinfection and eradicationWorld Journal of Gastroenterology, 2014
- Comparison of Sequencing Utility ProgramsThe Open Bioinformatics Journal, 2013
- Functional interactions between the gut microbiota and host metabolismNature, 2012
- Global patterns of 16S rRNA diversity at a depth of millions of sequences per sampleProceedings of the National Academy of Sciences of the United States of America, 2010
- Role of the gut microbiota in defining human healthExpert Review of Anti-infective Therapy, 2010
- Greengenes, a Chimera-Checked 16S rRNA Gene Database and Workbench Compatible with ARBApplied and Environmental Microbiology, 2006
- Maximum growth rates and possible life strategies of different bacterioplankton groups in relation to phosphorus availability in a freshwater reservoirEnvironmental Microbiology, 2006